Incretins: what is known, new and controversial in 2013?

Détails

ID Serval
serval:BIB_332AD78EFBA4
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Editorial
Collection
Publications
Titre
Incretins: what is known, new and controversial in 2013?
Périodique
Diabetes and Metabolism
Auteur(s)
Burcelin R., Thorens B.
Collaborateur(s)
European Club for the study of GLP-1 (EuCSGLP-1)
ISSN
1878-1780 (Electronic)
ISSN-L
1262-3636
Statut éditorial
Publié
Date de publication
2013
Volume
39
Numéro
2
Pages
89-93
Langue
anglais
Résumé
Glucagon-like peptide (GLP)-1 action involves both endocrine and neural pathways to control peripheral tissues. In diabetes the impairment of either pathway may define different subsets of patients: some may be better treated with GLP-1 receptor agonists that are more likely to directly stimulate beta-cells and extrapancreatic receptors, while others may benefit from dipeptidyl peptidase (DPP)-4 inhibitor treatments that are more likely to increase the neural gut-brain-pancreas axis. Elevated plasma concentrations of GLP-1 associated with agonist treatment or bariatric surgery also appear to exert neuroprotective effects, ameliorate postprandial and fasting lipids, improve heart physiology and protect against heart failure, thereby expanding the possible positioning of GLP-1-based therapies. However, the mechanisms behind GLP-1 secretion, the role played by proximal and distal intestinal GLP-1-producing cells as well as the molecular basis of GLP-1 resistance in diabetes are still to be ascertained. The pharmacological features distinguishing GLP-1 receptor agonists from DPP-4 inhibitors are discussed here to address their respective positions in type 2 diabetes.
Mots-clé
Incretins, Autonomic nervous system, DPP4, Heart, GIP
Pubmed
Web of science
Création de la notice
04/07/2013 19:51
Dernière modification de la notice
20/08/2019 13:19
Données d'usage